End-of-day quote
Other stock markets
|
||
- | - |
10/05 | UBS Adjusts Rocket Pharmaceuticals Price Target to $51 From $54, Maintains Buy Rating | MT |
10/05 | Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise | MT |